A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy-Reference-Cited by-同舟云学术

A phase II trial evaluating the feasibility of adding bevacizumab to standard osteosarcoma therapy

Published:2017-07-03 Issue:7 Volume:141 Page:1469-1477
ISSN:0020-7136
Container-title:International Journal of Cancer
language:en
Short-container-title:Int. J. Cancer

Author:

Navid Fariba¹²^ORCID,Santana Victor M.¹²,Neel Michael³,McCarville M. Beth⁴⁵,Shulkin Barry L.⁴⁵,Wu Jianrong⁶,Billups Catherine A.⁶,Mao Shenghua⁶,Daryani Vinay M.⁷,Stewart Clinton F.⁷,Kunkel Michelle¹,Smith Wendene¹,Ward Deborah⁸,Pappo Alberto S.¹²,Bahrami Armita⁹,Loeb David M.¹⁰,Reikes Willert Jennifer¹¹,Rao Bhaskar N.³¹²,Daw Najat C.¹³

Affiliation:

1. Department of OncologySt. Jude Children's Research HospitalMemphis TN

2. Department of PediatricsUniversity of Tennessee Health Science CenterMemphis TN

3. Department of SurgerySt. Jude Children's Research HospitalMemphis TN

4. Department of Diagnostic ImagingSt. Jude Children's Research HospitalMemphis TN

5. Department of RadiologyUniversity of Tennessee Health Science CenterMemphis TN

6. Department of BiostatisticsSt. Jude Children's Research HospitalMemphis TN

7. Department of Pharmaceutical SciencesSt. Jude Children's Research HospitalMemphis TN

8. Department of Pharmaceutical ServicesSt. Jude Children's Research HospitalMemphis TN

9. Department of PathologySt. Jude Children's Research HospitalMemphis TN

10. Department of OncologyDivision of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins UniversityBaltimore MD

11. Pediatric Hematology/Oncology/Blood and Marrow TransplantRady Children's HospitalSan Diego CA

12. Department of SurgeryCollege of Medicine, University of Tennessee Health Science CenterMemphis TN

13. Division of PediatricsMD Anderson Cancer CenterHouston TX

Funder

CORE

NCI

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ijc.30841

Reference44 articles.

1. Metastatic osteosarcoma

2. Primary Metastatic Osteosarcoma: Presentation and Outcome of Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols

3. Osteosarcoma: The Addition of Muramyl Tripeptide to Chemotherapy Improves Overall Survival—A Report From the Children's Oncology Group

4. Long-term results of the co-operative German–Austrian–Swiss osteosarcoma study group’s protocol COSS-86 of intensive multidrug chemotherapy and surgery for osteosarcoma of the limbs

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Upregulated ATG4B Predicts Poor Prognosis and Correlates with Angiogenesis in Osteosarcoma;2024-09-12

2. Targeted anti-angiogenesis therapy for advanced osteosarcoma;Frontiers in Oncology;2024-08-26

3. Part II: Adaptive designs in pediatric clinical trials: specific examples, comparison with adult trials and a discussion for the child health community;2024-01-10

4. Artificial intelligence-based radiomics in bone tumors: Technical advances and clinical application;Seminars in Cancer Biology;2023-10

5. Synergistic anti-tumour activity of ginsenoside Rg3 and doxorubicin on proliferation, metastasis and angiogenesis in osteosarcoma by modulating mTOR/HIF-1α/VEGF and EMT signalling pathways;Journal of Pharmacy and Pharmacology;2023-07-27